Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

Next Previous
Trial Profile

A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Acronyms Study
  • Sponsors Algernon Pharmaceuticals

Most Recent Events

  • 19 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 06 Jul 2021 According to an Algernon Pharmaceuticals media release, the company will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19 based on overall findings of the Phase 2b COVID-19 study final data set, the global rate of vaccinations to date, other COVID-19 drug treatment programs under development, and the projected trial size, costs and timelines needed to successfully complete a Phase 3 trial and feedback recently received from the U.S. FDA regarding the end of Phase 2 meeting.
  • 12 May 2021 Results presented in Algernon Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top